The Federal Trade Commission scored a landmark victory in the insulin pricing battle on February 4, 2026, when it secured a settlement with Express Scripts that could lower patients’ out-of-pocket insulin costs by up to $7 billion over the next decade. This settlement represents the most significant government action to date against the pharmaceutical supply chain dysfunction that has made insulin—a 100-year-old, life-sustaining medication—unaffordable for millions of Americans. However, it’s one outcome among hundreds of pending lawsuits.
As of January 2026, 444 separate cases remain consolidated in federal court under what’s known as MDL 3080 (Multidistrict Litigation), with a 370% surge in filed lawsuits between December 2024 and June 2025, signaling that the public’s legal battle against manufacturers and pharmacy benefit managers is far from over. This article explains what the insulin price-fixing class action litigation encompasses, how the recent FTC settlement with Express Scripts affects patients, what settlements have already been reached (and rejected), where the remaining cases stand, and what rights patients may have if they’ve paid inflated insulin prices. The core issue is simple in concept but complex in execution: pharmaceutical manufacturers, pharmacy benefit managers, and pharmacy chains allegedly conspired—or at minimum, created market conditions—where insulin list prices skyrocketed while rebates were hidden from patients at the point of sale, leaving patients to bear the financial burden.
Table of Contents
- What Is the Insulin Manufacturer Price-Fixing Antitrust Litigation About?
- The FTC Express Scripts Settlement—What Changed and What Didn’t
- Eli Lilly’s Rejected Settlement and Minnesota’s Standalone Deal
- The Current State of MDL 3080—444 Pending Lawsuits
- How PBMs, Manufacturers, and Pharmacies Allegedly Conspired
- Settlements to Date and Pending Litigation Against Other Defendants
- Future Outlook and Pending Reforms
What Is the Insulin Manufacturer Price-Fixing Antitrust Litigation About?
The insulin pricing litigation centers on an allegation that pharmacy benefit managers (PBMs) distorted the insulin market through a practice known as rebate-based competition. Rather than compete on net price—what insurers and patients actually pay after rebates—manufacturers were incentivized to inflate list prices and offer larger rebates to PBMs. The PBMs themselves captured much of the rebate value, while patients saw no benefit at the pharmacy counter. This creates a perverse system where a manufacturer raising its list price from $100 to $300 per vial can gain market share by offering a proportionally larger rebate to the PBM, even though the patient’s copay might still be $35—but that copay is now based on a inflated list price that affects deductibles, coinsurance, and uninsured patients. The Federal Trade Commission’s investigation found that this rebate-based competition had no legitimate purpose and served only to maintain artificially high list prices across the insulin market.
Express Scripts, one of the largest PBMs in the country, played a central role in perpetuating this system. As a concrete example, a patient with an insurance plan might need to pay the full list price to meet their deductible. If that list price is artificially inflated to $300 per vial due to the rebate system, the patient reaches their deductible faster and pays more out-of-pocket, even if the PBM is capturing a $100-per-vial rebate behind the scenes. The litigation has grown dramatically as the human impact became undeniable. Health plans, state attorneys general, and individuals have sued manufacturers (Eli Lilly, Novo Nordisk, and Sanofi), PBMs (Express Scripts, Optum, Caremark), and pharmacy chains over the same core allegation. What distinguishes the insulin cases from other pharmaceutical antitrust litigation is the urgency: insulin is a non-discretionary medication, meaning diabetics cannot choose to go without it, and they cannot shop for alternatives based on price the way consumers might with other drugs.
The FTC Express Scripts Settlement—What Changed and What Didn’t
On February 4, 2026, the FTC announced a settlement with Express Scripts that requires the PBM to fundamentally alter how it manages insulin formularies and rebates. The settlement mandates that Express Scripts move its Switzerland-based rebate aggregator, Ascent Pharmacy Benefit Manager, back to the United States. This move is significant because it closes a loophole where rebate information could be obscured by foreign operations. The FTC projects the settlement will generate approximately $750 billion in economic activity over a decade and reduce patients’ out-of-pocket insulin costs by up to $7 billion.
More concretely, Express Scripts must stop preferencing high-list-price drugs on its formularies and must delink compensation mechanisms from negotiated savings—meaning PBMs can no longer profit directly from the gap between list price and negotiated price. However, a critical limitation of this settlement is that it addresses only Express Scripts’ conduct. Two other major PBMs, Optum and Caremark, remain defendants in ongoing litigation as of February 2026. This means patients covered by Optum or Caremark plans may see no immediate cost relief, and the broader insulin market dysfunction could persist if these other settlement cases fail or drag on for years. Additionally, the settlement’s $7 billion savings projection assumes full implementation and cooperation, which may take years to materialize in actual patient relief.
Eli Lilly’s Rejected Settlement and Minnesota’s Standalone Deal
In April 2024, Eli Lilly proposed a $13.5 million settlement that would have capped insulin prices at $35 per month for a four-year period. The settlement was built around a class action certification—meaning if approved, it would have covered millions of insulin users nationwide. However, the presiding judge, Brian R. Martinotti of the U.S. District Court for the District of New Jersey, declined to certify the case as a class action, effectively killing the settlement.
This decision was pivotal: without class certification, litigants lack the use to negotiate a comprehensive settlement, and cases drag forward piece by piece. Separately, Minnesota reached its own settlement with Eli Lilly in February 2024, independent of the federal MDL litigation. Minnesota residents can now purchase eligible Eli Lilly and Sanofi insulin for $35 per month through January 23, 2030—a five-year commitment that extends beyond what the rejected federal settlement offered. Additionally, Eli Lilly committed to donating free insulin to 15 clinics serving low-income Minnesotans. This geographic patchwork illustrates a significant limitation of the litigation landscape: settlements and outcomes vary dramatically by state and jurisdiction. A patient in Minnesota has contractual protections that a patient in Texas or Florida does not, absent a broader national settlement.
The Current State of MDL 3080—444 Pending Lawsuits
As of January 2026, 444 lawsuits are consolidated in MDL 3080 before Judge Brian R. Martinotti in the U.S. District Court for the District of New Jersey. The sheer volume represents a seismic shift in litigation momentum. Between December 2024 and June 2025 alone, cases surged from approximately 85 to over 400—a 370% increase driven primarily by self-funded health plans realizing they have standing to sue for overcharges they absorbed. This growth signals that the litigation is far from conclusion and will likely proceed through discovery, motion practice, and potentially trial over the next several years.
The challenge for plaintiffs is that consolidation in an MDL is a double-edged sword. On one hand, consolidation prevents duplicate discovery and reduces court docket strain. On the other hand, it means that a single judge’s decision on class certification or summary judgment can affect hundreds of cases simultaneously. Judge Martinotti’s April 2024 decision to deny class certification in the Eli Lilly settlement is a cautionary example: it derailed a settlement that could have provided immediate relief to millions. Moving forward, any motion to certify a class or approve a settlement will carry immense weight. A practical tradeoff is that self-funded health plans (often large employers) have stronger use as individual plaintiffs with quantifiable damages, while consumers with standard insurance may have weaker claims unless a class is certified.
How PBMs, Manufacturers, and Pharmacies Allegedly Conspired
The FTC’s core allegation, supported by evidence in ongoing MDL 3080 cases, is that pharmaceutical manufacturers (particularly Eli Lilly, Novo Nordisk, and Sanofi), PBMs (Express Scripts, Optum, Caremark), and pharmacy chains created an ecosystem where list prices for insulin became untethered from actual cost or value. Manufacturers inflated list prices knowing that PBMs would accept them in exchange for rebates. PBMs then used these inflated list prices as benchmarks to increase copay tiers and patient cost-sharing. Meanwhile, pharmacy chains benefited from higher prices on their shelves, even as rebates flowed upstream.
A critical warning: not every insulin price increase necessarily constitutes illegal conduct. Manufacturers argue they raise prices to fund research and development, and PBMs argue rebates benefit insured populations by lowering premiums. However, when price increases occur in lockstep across competitors with no corresponding innovation or cost decrease, and when rebates are structured to incentivize higher list prices rather than lower net costs, the conduct crosses into antitrust territory. The MDL litigation will hinge on documentary evidence showing conscious parallel conduct or explicit coordination—something the FTC claims to have found in Express Scripts’ internal communications regarding Ascent’s rebate practices.
Settlements to Date and Pending Litigation Against Other Defendants
Beyond the Eli Lilly proposal (rejected) and Minnesota deal, there have been limited successful settlements. The Express Scripts settlement announced in February 2026 is the most significant to date, but it is a regulatory settlement with the FTC, not a class action settlement paying consumers directly. Optum and Caremark remain active defendants in MDL 3080 and related cases. If either settles, it could unlock a broader national resolution; if both continue to litigation, expect the MDL to grind through discovery for several more years.
State attorneys general have also filed parallel cases. Beyond Minnesota, states including South Carolina, Texas, and New York have initiated their own insulin price-fixing investigations. These state-level actions, while potentially slower, may result in state-specific settlements that provide direct relief to state residents and Medicaid programs. However, patients in states without active AG investigations have limited recourse outside the federal MDL.
Future Outlook and Pending Reforms
The express settlement with Express Scripts suggests the FTC is willing to pursue both regulatory settlements and support for class litigation simultaneously. However, structural reform—preventing future insulin price-fixing—will require congressional action or sustained litigation victories. The settlement’s requirement that Express Scripts relocate Ascent and delink rebate compensation is a start, but it does not address the fundamental incentive structure that allows manufacturers to inflate list prices.
Looking ahead, two scenarios are plausible. First, other PBM and manufacturer defendants might settle over the next 12-24 months, resulting in a patchwork of regional and company-specific deals, much like the Eli Lilly Minnesota settlement. Second, MDL 3080 could proceed to summary judgment or trial, with Judge Martinotti potentially certifying a class action on appeal or in response to evolving evidence. The 444 pending cases represent millions of dollars in claimed overcharges, and settlements, once reached, could exceed $1 billion—particularly if class certification is granted.